NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Drug-induced kidney injury, or nephrotoxicity, is a common complication in clinical medicine that happens when drugs damage the kidneys. Nephrotoxicity can occur with anti-inflammatory, antibacterial, ...
Applicants to the Ph.D. program Concentrations in Medicinal Chemistry, Pharmaceutics and Pharmacology must have, or nearly have, at least a Bachelor’s degree in pharmacy, biology, biochemistry, ...
School of Materials Sciences, Indian Association for the Cultivation of Science, Kolkata 700032, India ...
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...